NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Cardio Diagnostics Holdings (CDIO) and Molecular Precision in Coronary Heart Disease Detection
Cardio Diagnostics Holdings (CDIO) has developed molecular tests using epigenetics and genetics to detect coronary heart disease (CHD) earlier, addressing the blind spot where about 50% of individuals with CHD lack traditional risk factors and conventional risk calculators have only 39% sensitivity.
The article discusses Cardio Diagnostics Holdings (CDIO) and its development of molecular precision tests based on epigenetics and genetics to improve early detection of coronary heart disease (CHD), which is a leading cause of death in the US.
It is significant because approximately 50% of individuals with CHD do not present with traditional risk factors, and conventional risk calculators have only 39% sensitivity, meaning many people who appear healthy actually have CHD. CDIO's tests aim to detect CHD earlier to prevent cardiac events.
Traditional assessment relies on factors like cholesterol, blood pressure, smoking, diabetes, family history, and weight, which were not designed to capture the full biological picture of how heart disease develops, leading to many cases being missed.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics that examine how genes are expressed and regulated at the molecular level, providing a more precise biological assessment of CHD risk.
Coronary heart disease remains the leading cause of death in the United States.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements involve risks and uncertainties, and the article advises not to place undue reliance on them, referring to risk factors in the Company's SEC filings.
The article is likely targeted at investors, healthcare professionals, and individuals interested in cardiovascular health and innovative diagnostic technologies.